In conclusion, this study demonstrated appropriate de-escalation of adjuvant radiotherapy for women 70 years of age or older with cN0, T1, ER+, HER2– IBC during the COVID-19 pandemic without a change in rates of radiotherapy receipt among patients with high-risk breast cancer. This evidence concerns the gene ERBB2 and breast carcinoma.